Fig. 5

Blood compatibility and biocompatibility of CGP. a Microscopic images of erythrocyte aggregation in different treatment groups. b, c Hemolytic effects in different treatment groups. d Cell Counting Kit-8 assay of MC3T3-E1 and e hPDLSCs cells after treated with various groups. f Live/dead cell staining in different groups of hPDLSCs. Data are presented as mean ± SEM. In (c) n = 3, while in (d, e) n = 5. *p < 0.05, ***p ≤ 0.001, ****p ≤ 0.0001, ns: no significance. In (c) comparison between PBS versus other groups, while in (d, e) between the control group versus other groups